MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions
View by Date
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Pre-diagnosis physical activity habits are associated with age of diagnosis and postural instability in Parkinson’s disease

    M. Landers, K. Johnson, S. Johnson, J. Lyle, T. Ormsby, D. Salgo, J. Zorn, A. Murtishaw, A. Salazar, J. Kinney (Las Vegas, NV, USA)

  • Pre-Dopa DBS: is early deep brain stimulation able to modify the natural course of Parkinson’s disease?

    M. Porta, D. Servello, AR. Bona, E. Zekaj, G. Gonzalez-Escamilla, G. Groppa (Milan, Italy)

  • Pre-frontal activation during walking in Parkinson’s disease: the impact of attention

    S. Stuart, A. Giritharan, J. Quinn, M. Mancini (Portland, OR, USA)

  • Pre-status and status dystonicus in children and adolescents

    G. Garone, F. Graziola, F. Nicita, F. Frascarelli, F. Randi, M. Zazza, L. Cantonetti, F. Vigevano, CE. Marras, A. Capuano (Rome, Italy)

  • PRECISE-PD: From pathophysiology to precision medicine for Parkinson’s disease

    JC. Corvol, S. Durrleman, S. Lehericy, D. Devos, W. Meissner, E. Bezard, D. Grosset, H. Morris, O. Monchy, EA. Fon, F. Durif, F. Tubach, Y. de Rycke, O. Rascol (Paris, France)

  • Preclinical Development of a Novel Carbidopa/Levodopa Precision Olfactory Delivery (POD®) Drug-Device Combination Product for the Treatment of OFF Episodes in Parkinson’s Disease

    K. Satterly, G. Davies, B. Gajera, J. Wright, H. Lin, S. Muppaneni, K. To, S. Shrewsbury, J. Hoekman (Seattle, WA, USA)

  • Preclinical efficacy of drugs identified by IBM-Watson for repurposing to treat L-DOPA-induced dyskinesia

    N. Visanji, A. Lacoste, P. Ravenscroft, S. Spangler, S. Fox, A. Lang, J. Brotchie, T. Johnston (Toronto, ON, Canada)

  • Preclinical profile of dopamine D1PAM: A novel mechanism in clinical development for Lewy Body dementia

    K. Svensson, J. Beck, J. Hao, J. Schaus, X. Wang, B. Heinz, S. Mitchell, K. Wafford, C. Yang, L. Zhang, S. Castner, G. Williams, H. Marston, R. Bruns (Indianapolis, IN, USA)

  • Predicting active electrode selection from atlas based targets and probabilistic sweetspots in STN DBS

    T. Dembek, P. Reker, J. Petry-Schmelzer, V. Visser-Vandewalle, M. Barbe (Cologne, Germany)

  • Predicting domain specific cognitive impairment in Parkinson’s disease

    P. Zarifkar, J. Kim, C. La, P. Borghammer, K. Poston (Palo Alto, CA, USA)

  • « Previous Page
  • 1
  • …
  • 152
  • 153
  • 154
  • 155
  • 156
  • …
  • 217
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley